Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 9/20 | 0.53 |
| ▸ | UQCRB | P14927 | 2/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.52 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.47 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248358 | 0.87 | GRM4 (0.56) | GRM4GLO1KDM4EALDH1A1BDKRB1 | |
| SCHEMBL344138 | 0.85 | CCR9 (0.71) | CCR9HSD17B2 | |
| SCHEMBL1037932 | 0.76 | HSD17B2 (0.66) | CCR9UQCRBHSD17B2GLO1KDM4E | |
| SCHEMBL7587850 | 0.74 | HSD17B2 (0.79) | UQCRBHSD17B2GLO1KDM4EALDH1A1 | |
| SCHEMBL2747919 | 0.71 | LMNA (0.74) | CCR9UQCRBHSD17B2ALDH1A1PSD | |
| SCHEMBL2747439 | 0.70 | ACLY (0.60) | CCR9UQCRBHSD17B2ALDH1A1CA1 | |
| SCHEMBL10249380 | 0.70 | CCR9 (1.00) | CCR9 | |
| SCHEMBL16574547 | 0.69 | CCR9 (0.61) | CCR9UQCRBGLO1 | |
| SCHEMBL344136 | 0.69 | CCR9 (0.79) | CCR9 | |
| SCHEMBL344320 | 0.69 | CCR9 (0.79) | CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885UQCRB 4711/4885HSD17B2 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.